The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.

Szczegóły

Tytuł:: The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Autorzy:: Cherniawsky HM; University of Alberta, Edmonton, Alberta.
Kukreti V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON.
Reece D; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON.
Masih-Khan E; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Canadian Myeloma Research Group, Toronto, Ontario. .
McCurdy A; The Ottawa Hospital, Ottawa, Ontario.
Jimenez-Zepeda VH; Tom Baker Cancer Centre, Calgary, Alberta.
Sebag M; Department of Oncology, Division of Hematology, McGill University, Montreal, QC.
Song K; BC Cancer, Vancouver General Hospital, British Columbia.
White D; Queen Elizabeth II Health Sciences Centre. Dalhousie University, Halifax, Nova Scotia.
Stakiw J; Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Saskatchewan.
LeBlanc R; Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec.
Reiman A; Department of Oncology, Saint John Regional Hospital, Saint John, NB.
Aslam M; Allan Blair Cancer Centre, Regina, Saskatchewan.
Louzada M; London Regional Cancer Center, London, Ontario.
Kotb R; Cancer Care Manitoba, Winnipeg, Manitoba.
Gul E; Canadian Myeloma Research Group, Toronto, Ontario.
Atenafu E; Canadian Myeloma Research Group, Toronto, Ontario.
Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, Alberta.
Źródło:: Haematologica [Haematologica] 2021 Jun 01; Vol. 106 (6), pp. 1733-1736. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji:: Letter
Język:: English
Imprint Name(s):: Publication: 1999- : Pavia, Italy : Ferrata Storti Foundation
Original Publication: Pavia [etc.]
MeSH Terms:: Multiple Myeloma*/drug therapy
Multiple Myeloma*/epidemiology
Antineoplastic Combined Chemotherapy Protocols ; Bortezomib/therapeutic use ; Canada ; Dexamethasone/therapeutic use ; Disease-Free Survival ; Humans ; Lenalidomide/therapeutic use ; Maintenance Chemotherapy
References:: N Engl J Med. 1996 Jul 11;335(2):91-7. (PMID: 8649495)
N Engl J Med. 2012 May 10;366(19):1782-91. (PMID: 22571202)
Lancet Oncol. 2014 Nov;15(12):e538-48. (PMID: 25439696)
Blood. 2004 Nov 15;104(10):3052-7. (PMID: 15265788)
J Clin Oncol. 2017 Oct 10;35(29):3279-3289. (PMID: 28742454)
Leukemia. 2014 Feb;28(2):258-68. (PMID: 23868105)
N Engl J Med. 2012 May 10;366(19):1770-81. (PMID: 22571201)
J Clin Oncol. 2010 Feb 10;28(5):800-7. (PMID: 20048187)
Lancet Oncol. 2016 Aug;17(8):e328-e346. (PMID: 27511158)
Lancet Oncol. 2019 Jan;20(1):57-73. (PMID: 30559051)
N Engl J Med. 2014 Sep 4;371(10):895-905. (PMID: 25184862)
Substance Nomenclature:: 69G8BD63PP (Bortezomib)
7S5I7G3JQL (Dexamethasone)
F0P408N6V4 (Lenalidomide)
Entry Date(s):: Date Created: 20201015 Date Completed: 20210527 Latest Revision: 20210612
Update Code:: 20240105
PubMed Central ID:: PMC8168484
DOI:: 10.3324/haematol.2020.259093
PMID:: 33054120
: Opinia redakcyjna

Full Text Finder

Informacja